Table of Contents
What changed
Revenue rose 38.7% to $1,191.7m and PBT lifted 370.1% to $604.1m, with profit from continuing operations up 430.3% to $561.6m. Headline NPAT, however, fell 23.7% to $891.7m because the discontinued-operation after-tax gain shrank to $330.1m from $1,125.8m in FY22. Operating cash flow collapsed to $8.8m from $82.8m (-89.4%) while capex rose to $137.4m from $115.6m, taking pre-lease free cash flow to -$128.6m versus -$32.8m.
The balance sheet was reshaped: gross borrowings fell to $799.9m from $3,428.1m, cash eased to $774.5m from $851.0m, and implied net debt dropped to roughly $25.4m from $2,577.1m. Equity climbed to $5,810.7m (+13.0%). Segment mix shifted materially, with Diagnostic Imaging now the largest revenue contributor at $601.2m (31.7% of revenue) while the Manawa Energy line replaces the prior-year Trustpower NZ comparator. The declared final dividend is 12.5c per share, up from 12.0c.
What matters
- PBT is the cleaner read, not NPAT. The effective tax rate fell to 7.0% from 17.6% and the $330.1m discontinued-operation gain inflates the bottom line. Continuing-operations profit up 430% is the relevant signal; the 23.7% NPAT decline is an artefact of a smaller disposal gain year-on-year.
- Cash conversion deteriorated sharply. Operating cash flow of $8.8m against $604.1m of PBT is a wide gap, and capex of $137.4m (11.5% of revenue) left pre-lease FCF at -$128.6m. The 12.5c dividend is not covered by pre-lease free cash flow on either year.
- Leverage direction is the structural story. Gross borrowings cut by $2,628.2m and near-zero implied net debt reflect the portfolio transition (including the Trustpower-to-Manawa separation), not organic deleveraging. Reported ROE nonetheless weakened to 15.3% from 22.7% on the enlarged equity base.
Expectations
No quantified forward-work balance, EBITDAF reconciliation, or formal financial guidance was supplied, so the release cannot be benchmarked against a stated target. On half-on-half shape, HY23 revenue of $604.4m implies H2 revenue of roughly $587.3m, so the year was broadly evenly split on the top line, while H2 delivered the larger share of NPAT (H1 was 39.3% of the full year). With no target or run-rate anchor disclosed, the release supports a read that continuing-operations earnings scaled materially in FY23 but does not support any inference about FY24 revenue, margin, or capex intensity beyond what segment composition implies.
Quality of result
Mixed, and noticeably weaker than the headlines suggest. Continuing-operations earnings growth is real but partially flattered by a 10.6pp lower effective tax rate and by a segment mix that is not strictly like-for-like given the Trustpower-to-Manawa transition. Associate share of profit more than doubled to $653.4m and drives much of the continuing-ops result, meaning a large portion of reported earnings is equity-accounted rather than cash-generative at the parent. The 89.4% fall in operating cash flow, against rising capex and a pre-lease FCF of -$128.6m, indicates the FY23 IFRS earnings step-up is not being mirrored in group cash generation. The dramatic fall in gross borrowings is balance-sheet-assisted (portfolio transition), not operationally driven.
Unresolved
- What drove the operating cash flow collapse to $8.8m — working-capital movements, interest/tax timing, or deconsolidation effects from the portfolio transition?
- Proportionate EBITDAF is referenced but no numeric reconciliation was supplied, so the bridge from IFRS PBT to the non-GAAP earnings measure management emphasises is not verifiable here.
- How much of the $653.4m associate contribution is cash-distributed versus accrued, and what is the look-through leverage once CDC, Longroad and other associates are included (implied net debt of $25.4m at parent level understates group economic leverage).
- Whether the 12.5c declared dividend is the final component or a full-period figure is not fully specified; the payout against continuing-ops NPAT (14.1%) is modest, but against pre-lease FCF the dividend is uncovered.
- This briefing cannot assess proportionate EBITDAF, look-through associate leverage, or forward-period earnings trajectory because no reconciliation, net-debt disclosure on a proportionate basis, or guidance was provided in the supplied materials.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $1191700m | $858900m | +38.7% ↑ |
| Net profit after tax | $891.7m | $1169.3m | -23.7% ↓ |
| Net cash inflow from operating activities | $8.8m | $82.8m | -89.4% ↓ |
| Final dividend per share | 12.5c | 12.0c | +4.2% ↑ |
| Operating profit | $696.1m | $205.8m | +238.2% ↑ |
| Profit before tax | $604.1m | $128.5m | +370.1% ↑ |
| Total assets | $10188.8m | $9851.8m | +3.4% ↑ |
Reference: annolyse.ai/briefings/ift-fy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Manawa Energy | $482.2m | $1019.7m | $444.3m | -28.6pp |
| Mint Renewables | $0m | — | −$2m | n/a |
| Wellington International Airport | $139.8m | $95.6m | $25.2m | +2.3pp |
| Diagnostic Imaging | $601.2m | $440.5m | $44.2m | +8.4pp |
| Gurīn Energy | $0.7m | — | −$16.8m | n/a |
| Associates | — | — | $653.4m | n/a |
| All other segments and corporate | $147.8m | $87.4m | −$129.9m | +3.2pp |
Reference: annolyse.ai/briefings/ift-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| PBT growth | +370.1% | — | cleaner earnings measure |
| Effective tax rate | 7.0% | 17.6% | — |
| FCF pre-lease | −$128.6m | −$32.8m | −$95.8m |
| FCF / NPAT | -14.4% | -2.8% | complementary conversion metric |
| Capex % revenue | 11.5% | 13.5% | — |
| Capex | $137.4m | $115.6m | +$21.8m |
| Net debt | $25.4m | $2577.1m | −$2551.7m |
| Gross borrowings | $799.9m | $3428.1m | −$2628.2m |
| Payout ratio vs NPAT | 14.1% | — | — |
| Payout ratio vs FCF pre-lease | -97.6% | — | not covered |
| ROE (annualised) | 15.3% | 22.7% | Weakening |
| HY23 share of FY23 revenue | 50.7% | — | Other half was 49.3% |
| HY23 share of FY23 NPAT | 39.3% | — | Other half was 60.7% |
| Profit from continuing operations | $561.6m | $105.9m | +$455.7m |
| Discontinued operation after tax | $330.1m | $1125.8m | −$795.7m |
Reference: annolyse.ai/briefings/ift-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.